Navigation Links
The Chiesi Group Lands in the United States
Date:5/7/2009

lready a market leader.

The availability of a solid commercial base in this country will, in future, allow us to create synergies and new sales outlets for some of the projects we are developing in the respiratory area."

"This agreement means a major transformation for Cornerstone, giving us a new respiratory drug, major capital, and the possibility of accessing future products," affirmed Craig Collard, chairman and CEO of Cornerstone.

Curosurf is an excellent product with a leadership position in the market, a solid intellectual property situation, and an excellent growth potential. In addition, Chiesi's strategic investment brings 15.8 million dollars to our coffers, a significant injection of cash that can be used to continue to develop our products in the pipeline, to strengthen our marketing network and to further improve our position in the respiratory market.

Furthermore, this additional capital puts us in a favourable position to evaluate and consolidate the opportunities for acquiring high-quality respiratory products under license. Finally, the agreement allows us to work in close contact with Chiesi, one of the most respected and successful European pharmaceutical firms.

Chiesi Profile

Founded in 1935 in Parma, in 2008 the Chiesi Group turned over 748 million Euros, posting a +14.3%, almost three times the average growth for the European market. Active primarily in the area of respiratory therapeutics and rare diseases, the Group has 22 associated companies worldwide and is present in more than 50 countries with its drugs, produced at its facilities in Parma, Blois (France) and Santana de Parnaiba (Brazil).

In 2008 investments in R&D were 108 million Euros, equal to 14.4% of revenues, bringing us close to the target of 15% that the company intends to reach and maintain in the next few years. To the three research centres in Parma, Pa
'/>"/>

SOURCE Chiesi Farmaceutici S.p.A.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
2. DuPont Statement on Obama Administration Biofuels Interagency Working Group
3. The Arcas Group Appoints Executive Vice President
4. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
5. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
6. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
7. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
8. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
9. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
10. Disabled and other vulnerable groups more susceptible to terrorism fears
11. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 HubCast® Inc. ( http://www.hubcast.com ), ... the expansion of its Global Print Supply Chain with ... the world’s largest cities across 75 countries globally. ... countries providing global enterprises ease, speed, reach, quality, cost ... online order to real-world delivery at postal address around ...
(Date:3/3/2015)... March 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, announced today that it will ... March 12, 2015 after the market close. The Company will ... day. Interested parties may access the call ... 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "RNAi - ... , Because of its ability to silence ... been adopted as the research tool to discriminate gene ... RNAi can be designed to target every gene in ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Global Biotechnology Company Adopts Pharsight,s Groundbreaking ... Automation Software, ... ), a leading provider of software and strategic,services for optimizing clinical ... purchased WinNonlin AutoPilot.,This sale marks Pharsight,s third new customer win since ...
... Denosumab is a new drug being,studied to prevent fractures ... phase 3 clinical trial using denosumab were presented,Friday evening ... MD, from the Seattle Cancer Care Alliance., Denosumab ... osteoclasts -- specialized cells that break down bone. Because ...
... Dec. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that following the meeting of ... has received a recommendation to,continue MAESTRO-01, its pivotal ... of secondary progressive multiple sclerosis., This was ...
Cached Biology Technology:Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 2Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 3New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... or Genetically Modified Organisms, may raise concerns of genes escaping ... But what is the real risk that traits associated ... wild relatives? Interest in plant ecology, crop production and ... University of Nebraska and USDA-ARS to investigate how gene flow ...
... Newport News, Virginia, was walking her employer,s Westie around the ... mysterious blob floating in the water. Co-worker Charlie Schmuck ... by the lake, saw the object, and asked everyone else ... it was "a huge dead snake." Charlie thought it ...
... The rate at which lead poisoning has struck young Rhode ... a Brown University-led geographic analysis of comprehensive health department data ... cases of lead poisoning, researchers have been able to help ... that 12-year period, some census blocks in the state had ...
Cached Biology News:If GMO genes escape, how will the hybrids do? 2If GMO genes escape, how will the hybrids do? 3VIMS scientists help solve mystery of 'alien pod' 2Lead poisoning maps in R.I. reveal huge disparities, guide cleanup 2